0000000000076154

AUTHOR

Laura Richert

showing 2 related works from this author

The Transcription Factor Promyelocytic Leukemia Zinc Finger Protein Is Associated With Expression of Liver‐Homing Receptors on Human Blood CD56bright…

2020

The transcription factor promyelocytic leukemia zinc finger protein (PLZF) is involved in the development of natural killer (NK) cells and innate lymphoid cells, including liver‐resident NK cells in mice. In human NK cells, the role of PLZF in liver residency is still unknown. Expression of PLZF in matched human peripheral blood‐ and liver‐derived NK cells and the association of PLZF expression with surface molecules and transcription factors relevant for tissue residency were investigated using multiparameter flow cytometry and assessing single‐cell messenger RNA (mRNA) levels. Intrahepatic cluster of differentiation (CD)56bright NK cells expressed significantly higher levels of PLZF than …

[SDV.IMM] Life Sciences [q-bio]/ImmunologyPopulationCellC-C chemokine receptor type 6Biology03 medical and health sciences0302 clinical medicinemedicinelcsh:RC799-869ReceptoreducationTranscription factor030304 developmental biology0303 health sciencesMessenger RNAeducation.field_of_studyHepatologyCluster of differentiationInnate lymphoid cellOriginal ArticlesSISTM3. Good healthmedicine.anatomical_structureCancer research[SDV.IMM]Life Sciences [q-bio]/ImmunologyOriginal Articlelcsh:Diseases of the digestive system. Gastroenterology030215 immunologyHepatology Communications
researchProduct

ESSAI RANDOMISÉ POUR ÉVALUER L’EFFICACITÉ ET LA SÉCURITÉ DE TRAITEMENTS CHEZ DES PATIENTS AMBULATOIRES ATTEINTS DE COVID-19 AYANT DES FACTEURS DE RIS…

2021

Context. The Covid-19 pandemic is of unprecedented magnitude and has had major social and health consequences. Primary care professionals, mainly general practitioners, ensure the care of most patients with Covid-19. An early-stage treatment administered to patients with risk factors for developing a severe disease could reduce hospitalization and death rates. No treatment is currently validated in this indication. Objectives. To evaluate the safety and efficacy of experimental candidate agents delivered in outpatient settings to reduce the risk of hospitalization or death in at-risk patients with early-stage proven Covid-19 and no indication for hospital admission. Methods. Multicentric, o…

treatment[SDV]Life Sciences [q-bio]protocolstrialInternalcontrolledclinical[SDV] Life Sciences [q-bio]earlyrandomizedoutpatientMedicineGeneralCovid-19
researchProduct